Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and...
Uloženo v:
| Vydáno v: | Arthritis Res Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2002
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC154429/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12716442/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar609 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|